Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Short Term Picks From the 'Whiz' Kid -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Miller who wrote (2641)	3/2/1999 12:01:00 AM
From: times 2	Respond to of 9115

I'am looking at FSOL. if it upturns, time to buy -also MRPS after it cools off for the next run.

To: Daniel Miller who wrote (2641)	3/2/1999 1:11:00 AM
From: Popiye	Read Replies (1) \| Respond to of 9115

(WGHI) Equity Research Report Issued on Westmark Group Holdings, Inc. BOCA RATON, Fla., March 1 /PRNewswire/ -- Burkenroad Equity Research (Burkenroad Reports) of New Orleans, La. has issued a stock research report with a "Buy" Recommendation on Westmark Group Holdings, Inc. (Nasdaq: WGHI). Copies of Burkenroad's report on Westmark can be accessed through various on-line investment services -- including First Call, Bloomberg Financial Services and Nelson's Directory of Investment Research -- or can be obtained directly by calling either: -- Peter F. Ricchiuti, Director of Research, Burkenroad Reports, (504) 862-8489, (c/o Marie Daigle) -- Louis J. Resweber, Westmark Capital Markets, toll-free: (888) 389-2266, (c/o Christina Domingue) Burkenroad Reports is an independent securities research organization affiliated with the A.B. Freeman School of Business at Tulane University. Burkenroad's research reports are subscribed to by more than 3,500 mostly institutional investors and portfolio managers, including 850 small-cap and micro-cap fund managers. The "Buy" recommendation is the highest rating awarded under Burkenroad's five-tiered rating system. Westmark Group Holdings Inc., through its subsidiary, Westmark Mortgage Corp., is engaged in the origination, purchase and sale of non-conforming, residential mortgage loans secured by a first or second lien on the borrower's primary place of residence. Most of these loans are made to borrowers with "A-," "B" and "C" rated (sub prime) credit histories who might not qualify for Federal-agency-conforming loans under traditional bank guidelines. Westmark pools its loans and sells them on a bulk basis to institutional investors. Westmark distinguishes itself from many of its peers in that it does not retain servicing rights on its loans, and all loans are sold monthly on a whole loan, cash basis, with revenues recognized only after the sale is completed. Common stock of Westmark trades on The Nasdaq Stock Market under the symbol "WGHI." Contact: Louis J. Resweber, 1-888-389-2266, Christina B. Domingue, 1-225-927-9330, or Amy M. Varisco, 1-225-927-9330, all of Westmark Group Holdings, Inc., or lou@wghi.com. SOURCE Westmark Group Holdings, Inc. CO: Westmark Group Holdings, Inc.; Burkenroad Equity Research; A.B. Freeman School of Business at Tulane University ST: Florida, Louisiana

To: Daniel Miller who wrote (2641)	3/2/1999 6:39:00 AM
From: Mr Metals	Read Replies (1) \| Respond to of 9115

otcbb.com otcbb.com otcbb.com otcbb.com MM

To: Daniel Miller who wrote (2641)	3/2/1999 8:43:00 AM
From: dexx	Respond to of 9115

DMRX was a sleeper that is waking up. Info below from new DMRX thread: DermaRx Corporation (OTCBB: DMRX) 284 S. Jackson St. Denver, CO 80206 (303) 333-4600 Pres. & CEO: Maryanne Carroll VP: Gerit Mulder Outstanding Shares: 9.87 million Float: Approximately 3 million Brief Overview of Company: DMRX works through its two wholly owned subsidiaries Dermedics and Wound Sciences, Inc. Dermedics manufactures and markets numerous products including HemorRx, BottomBetter, PsoRxin, DermaMed Cleanser and GeriMend Skin Therapy. Wound Sciences, Inc. provides wound protocol development for hospitals and nursing homes. A clinical evaluation of HemorRx was recently completed with very favorable results. 98% of the patients experienced sympton relief within 3 days. As a result, DMRX has entered into a distribution agreement with a drug store chain, RXPlus. I like what I see so far. My research shows that a little over a year ago this stock was trading at $1.00.